Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
Lessons in Innovation: Clark Turner’s Impact on Medical Imaging
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
Transforming Care for Severe AS Patients
Enhanced platform technology and the addition of a robust, high-quality CHO K-1 cell line decreases lead time to Investigational New Drug (IND)
Podium presentation showcases the clinical application of Precise™ MRD
Renowned neuroprosthetics expert joins BIOS to lead clinical strategy and advance development of the Universal Neural Interface.
CLARITY SIGNS HIGH-VOLUME COMMERCIAL-SCALE COPPER-64 SUPPLY AGREEMENT WITH NUSANO
The biomarker pTau 217 is associated with Alzheimer’s disease pathology and can be detected in plasma, providing a minimally invasive option to support other diagnostic tests.
Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants.
Congresssional Staffer Tours